{'fraction_non_alphanumeric': 0.03104575163398693, 'fraction_numerical': 0.006535947712418301, 'mean_word_length': 5.621621621621622, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical application of chemiluminescent immunoassay for thyroid stimulating hormone, free-T4 and intact-parathyroid hormone.

To meet the demands of clinical practice, rapid, sensitive and specific laboratory tests are essential. We evaluated the performance of a newer generation of chemiluminescent immunoassay (CLIA) system (Immulite, Diagnostic Products Corp, Los Angeles, CA, USA) and compared it with a popular immunoradiometric immunoassay (IRMA) system. The data of 158 patients whose thyroid function was assessed and that of another 158 patients whose parathyroid function was assessed were analyzed. The thyroid stimulating hormone (TSH) CLIA is an ultrasensitive TSH (us-TSH) assay that provides more detailed, reliable results for low TSH concentrations than TSH IRMA. Coupled with the free-T4 assay, the us-TSH assay enhances the ability to detect and monitor the status of thyroid dysfunction. Intact-parathyroid hormone (PTH) CLIA can detect lower serum intact-PTH levels, is more sensitive and is as reliable as IRMA. Combined with serum calcium levels and clinical conditions, it proved efficient and discriminated reliably between hypercalcemia associated with malignancy and that of hyperparathyroidism.